Clinical Trial Update: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for TQB2102 in HER2-negative breast cancer, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TQB2102

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING